Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Treatment of inappropriate sinus tachycardia with ivabradine



Inappropriate sinus tachycardia (IST) often causes palpitations, dyspnea, and exercise intolerance, that are generally treated with beta blockers and non-dihydropyridine calcium-channel antagonists. Ivabradine, a selective inhibitor of cardiac pacemaker If current, has recently emerged as an effective and safe alternative to conventional drugs for IST.


We performed a systematic overview of clinical studies on the therapeutic yield of ivabradine in patients with inappropriate sinus tachycardia, published in MEDLINE database from January 2000 to March 2015.


Overall, five case reports were found, all showing efficacy of ivabradine in subjects affected by IST. Eight non-randomized clinical studies demonstrated short- and medium-term safety and efficacy of ivabradine administration in IST, also in adjunction to or in comparison with metoprolol. One double-blind randomized crossover study also showed that ivabradine is superior to placebo for heart rate (HR) reduction and symptoms control in patients affected by IST.


Ivabradine is effective and safe in short- and medium-term treatment of IST. However, long-term follow-up studies and randomized studies comparing ivabradine with beta blockers are still lacking.

This is a preview of subscription content, log in to check access.



Beats per minute


Calcium-channel antagonists


Ejection fraction


Heart failure


Heart rate


Inappropriate sinus tachycardia


Left ventricular


Metabolic equivalents


  1. 1.

    Sheldon, R. S., Grubb, B. P., 2nd, Olshansky, B., Shen, W. K., Calkins, H., Brignole, M., et al. (2015). Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm, 12, e41–e63.

  2. 2.

    Still, A. M., Raatikainen, P., Ylitalo, A., Kauma, H., Ikäheimo, M., Antero Kesäniemi, Y., et al. (2005). Prevalence, characteristics and natural course of inappropriate sinus tachycardia. Europace, 7, 104–112.

  3. 3.

    Rubenstein, J. C., Freher, M., Kadish, A., & Goldberger, J. J. (2010). Diurnal heart rate patterns in inappropriate sinus tachycardia. Pacing and Clinical Electrophysiology, 33, 911–919.

  4. 4.

    Lin, D., Garcia, F., Jacobson, J., Gerstenfeld, E. P., Dixit, S., Verdino, R., et al. (2007). Use of noncontact mapping and saline-cooled ablation catheter for sinus node modification in medically refractory inappropriate sinus tachycardia. Pacing and Clinical Electrophysiology, 30, 236–242.

  5. 5.

    DiFrancesco, D. (2010). The role of the funny current in pacemaker activity. Circulation Research, 106, 434–446.

  6. 6.

    Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., et al. (2013). 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 34, 2949–3003.

  7. 7.

    McMurray, J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal, 14, 803–869.

  8. 8.

    Retegui, G., Quintero, M., Ruiz-Borrell, M., & Revello, A. (2009). Ivabradine as a treatment option for inappropriate sinus tachycardia. Revista Española de Cardiología, 62, 577–579.

  9. 9.

    Celebi, O. O., Canbay, A., Celebi, S., Aydogdu, S., & Diker, E. (2010). Inappropriate sinus tachycardia-successful treatment with ivabradine. Kardiologia Polska, 68, 935–937.

  10. 10.

    Schulze, V., Steiner, S., Hennersdorf, M., & Strauer, B. E. (2008). Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia. Cardiology, 110, 206–208.

  11. 11.

    Weyn, T., Stockman, D., & Degreef, Y. (2011). The use of ivabradine for inappropriate sinus tachycardia. Acta Cardiologica, 66, 259–262.

  12. 12.

    Wilson, D., & Crook, B. (2009). Ivabradine for inappropriate sinus tachycardia. British Journal of Cardiology, 16, 151–152.

  13. 13.

    Rakovec, P. (2009). Treatment of inappropriate sinus tachycardia with ivabradine. Wiener Klinische Wochenschrift, 121, 715–718.

  14. 14.

    Zellerhoff, S., Hinterseer, M., Felix Krull, B., Schulze-Bahr, E., Fabritz, L., Breithardt, G., et al. (2010). Ivabradine in patients with inappropriate sinus tachycardia. Naunyn-Schmiedebergs Arch Pharmacol, 382, 483–486.

  15. 15.

    Benezet-Mazuecos, J., Rubio, J. M., Farrè, J., Quiňones, M. A., Pepa, S. B., & Macìa, E. (2013). Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing and Clinical Electrophysiology, 36, 830–836.

  16. 16.

    Kaplinsky, E., Comes, F. P., Urondo, L. S., & Ayma, F. P. (2010). Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessment. Cardiology Journal, 17, 166–171.

  17. 17.

    Calò, L., Rebecchi, M., Sette, A., Martino, A., de Ruvo, E., Sciarra, L., et al. (2010). Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm, 7, 1318–1323.

  18. 18.

    Ptaszynski, P., Kaczmarek, K., Ruta, J., Klingenheben, T., & Wranicz, J. K. (2013). Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace, 15, 116–121.

  19. 19.

    Ptaszynski, P., Kaczmarek, K., Ruta, J., Klingenheben, T., Cygankiewicz, I., & Wranicz, J. K. (2013). Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. Journal of Cardiovascular Pharmacology and Therapeutics, 18, 338–344.

  20. 20.

    Wynn, G. J., Todd, D. M., Webber, M., Bonnett, L., McShane, J., Kirchhof, P., et al. (2014). The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace, 16, 965–972.

  21. 21.

    Cappato, R., Castelvecchio, S., Ricci, C., Bianco, E., Vitali-Serdoz, L., Gnecchi-Ruscone, T., et al. (2012). Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia. Journal of the American College of Cardiology, 60, 1323–1329.

  22. 22.

    Martino A, Sette A, Rebecchi M, de Ruvo E, Sciarra L, Calo’ L. Ivabradine versus bisoprolol for inappropriate sinus tachycardia. Abstract 14–9. ECAS Congress 2015. April 19, 2015.

  23. 23.

    Suffredini, S., Stillitano, F., Comini, L., Bouly, M., Brogioni, S., Ceconi, C., et al. (2012). Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. British Journal of Pharmacology, 165, 1457–1466.

Download references

Author information

Correspondence to Leonardo Calo.

Ethics declarations

Conflicts of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Annamaria, M., Lupo, P.P., Foresti, S. et al. Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol 46, 47–53 (2016).

Download citation


  • Ivabradine
  • Inappropriate sinus tachycardia
  • Tachy-cardiomyopathy